Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853033 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Phase 1 study of Rheumatoid Arthritis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 4
- Study locations
NCT01853033: Completed Phase 1 study of Rheumatoid Arthritis, sponsored by AbbVie.
NCT01853033 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by AbbVie. The registered enrollment target is 19 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01853033, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of ABT-122 in subjects with Rheumatoid Arthritis.
Primary Outcome
Collect all adverse events at each visit
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ABT-122
Study Locations (4)
Kansas
- Site Reference ID/Investigator# 108655 - Lenexa
North Carolina
- Site Reference ID/Investigator# 107115 - Raleigh
Pennsylvania
- Site Reference ID/Investigator# 118964 - Duncansville
Texas
- Site Reference ID/Investigator# 100780 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT01853033 record still lists
NCT01853033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01853033 reports a single indexed study location in Kansas, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01853033 about?
NCT01853033 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of ABT-122 in subjects with Rheumatoid Arthritis.
What is the current status of trial NCT01853033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2013-07. Estimated completion is 2014-05.
What conditions does trial NCT01853033 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01853033?
The interventions under investigation include: Placebo (BIOLOGICAL), ABT-122 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01853033?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01853033 being conducted?
This trial has 4 study locations across Kansas, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01853033's enrollment target sits among peer trials
19 181st of 197 higher than 17 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia